Options market pricing implies that Moderna Inc. shares may move approximately 4.2% when the company issues its quarterly earnings report on July 31 before markets open. That figure is derived from options data compiled by Bloomberg and reflects the market's expectation of near-term volatility around the scheduled release.
Looking at recent history, Moderna's actual share-price reactions to earnings have sometimes outpaced what options had implied. In three of the last eight reporting periods, the stock moved more than the options market anticipated. Notably, on August 1, 2025, the shares plunged 18.8% even though the options implied a 7.6% move. A similar pattern occurred on May 1, 2026, when the stock fell 14.2% against a 9.2% implied move.
The May 1, 2026 report illustrates how options-implied moves can understate realized volatility: traders had priced in a 9.2% swing but the equity posted a 14.2% drop following the release. Earlier in the year, the February 13, 2026 earnings announcement produced a gain of 3.3% while the options market had anticipated a 9.6% move.
Over the past two years, Moderna's most pronounced post-earnings reaction occurred on August 1, 2024, when shares declined 20.3% despite options implying a much smaller 7.9% change. These past outcomes highlight that actual stock responses to earnings can diverge materially from options-derived expectations.
Market participants tracking Moderna ahead of the July 31 release will be weighing the 4.2% implied move against the company's recent pattern of occasional outsized reactions. Investors and traders often use the implied move as a gauge for potential volatility, but historical episodes for this stock show that realized outcomes may be substantially larger.
Contextual note: The implied move figure referenced here is taken from options pricing data and represents market consensus expectation for near-term volatility surrounding the earnings event.